INmune Bio (INMB) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

INmune Bio Revenue Highlights


Latest Revenue (Y)

$-155.00K

0

INmune Bio Revenue by Period


INmune Bio Revenue by Year

DateRevenueChange
2023-12-31$-155.00K-141.44%
2022-12-31$374.00K106.63%
2021-12-31$181.00K1558.12%
2020-12-31$10.92K-99.99%
2019-12-31$77.69M100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31--

INmune Bio generated $-155.00K in revenue during NA 2023, up -141.44% compared to the previous quarter, and up -Infinity% compared to the same period a year ago.

INmune Bio Revenue by Quarter

DateRevenueChange
2024-09-30-100.00%
2024-06-30--100.00%
2024-03-31$14.00K-50.00%
2023-12-31$28.00K-34.88%
2023-09-30$43.00K-6.52%
2023-06-30$46.00K21.05%
2023-03-31$38.00K-60.82%
2022-12-31$97.00K-1.02%
2022-09-30$98.00K512.50%
2022-06-30$16.00K-90.18%
2022-03-31$163.00K-
2021-12-31$163.00K1064.29%
2021-09-30$14.00K100.00%
2021-06-30--100.00%
2021-03-31$4.00K-63.36%
2020-12-31$10.92K100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--100.00%
2019-12-31$77.69M100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31--

INmune Bio generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

INmune Bio Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
TCRXTScan Therapeutics$21.05M-
CUECue Biopharma$5.49M$1.72M
TFFPTFF Pharmaceuticals$733.87K$650.22K
ANIXAnixa Biosciences$210.00K-
ANEBAnebulo Pharmaceuticals--
ANTXAN2 Therapeutics--
AVTEAerovate Therapeutics--
DBTXDecibel Therapeutics--
BIVIBioVie--
INABIN8bio--
SAVACassava Sciences--
CGTXCognition Therapeutics--
ELYMEliem Therapeutics--
DRMADermata Therapeutics--
PYPDPolyPid--
AVXLAnavex Life Sciences--
INMBINmune Bio$-155.00K-

INMB Revenue FAQ


INmune Bio's yearly revenue for 2023 was $-155K, representing a decrease of -141.44% compared to 2022. The company's yearly revenue for 2022 was $374K, representing an increase of 106.63% compared to 2021. INMB's yearly revenue for 2021 was $181K, representing an increase of 1558.12% compared to 2020.

INmune Bio's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a -100.00% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). INMB's quarterly revenue for Q1 2024 was $14K, a -50.00% decrease from the previous quarter (Q4 2023), and a -63.16% decrease year-over-year (Q1 2023).

INmune Bio's revenue growth rate for the last 3 years (2021-2023) was -185.64%, and for the last 5 years (2019-2023) was -100.20%.